Related Experiment Video
Updated: Apr 28, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
2.0K
Real-World Impact of Insurance Changes on Long-acting Cabotegravir Plus Rilpivirine Delivery
Jennifer M Davis1, Jennifer O'Neill1, Elizabeth Lyden2
1Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Open Forum Infectious Diseases
|April 27, 2026
Summary
Nearly half of patients on long-acting injectable HIV medications experienced insurance changes, potentially delaying crucial treatment. This highlights insurance barriers impacting adherence to injectable antiretroviral therapy.
Area of Science:
- Infectious Diseases
- Pharmacology
- Health Services Research
Background:
- Long-acting injectable antiretroviral therapy (ART) presents an alternative to daily oral medications for HIV management.
- Insurance-related barriers are a significant concern for the consistent implementation of injectable ART.
Purpose of the Study:
- To determine the frequency of insurance changes among patients receiving long-acting injectable cabotegravir plus rilpivirine in the United States.
- To assess the impact of these insurance changes on treatment continuity.
Main Methods:
- Retrospective cohort study analyzing patient data.
- Examination of insurance records and injection schedules.
- Focus on a United States-based patient population.
Main Results:
- Approximately 50% of patients encountered changes in their insurance coverage during the study period.
- Insurance changes were associated with potential disruptions and delays in scheduled injectable ART administration.
Conclusions:
- Insurance transitions pose a substantial risk to the continuity of care for patients on long-acting injectable HIV treatment.
- Addressing insurance barriers is critical for successful long-term implementation of this important therapeutic option.
Related Concept Videos
01:20Modified-Release Drug Delivery Systems: Influencing Factors
200
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
200
01:30Modified-Release Drug Delivery Systems: Bioavailability
163
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
163
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
01:19Modified-Release Drug Delivery Systems: Overview
231
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
231
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
253
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
253
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
168
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
168